Add to ORKGPhase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemi
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, a...
antileukemic activity in cell lines and primary cultures of acute myeloid leukemi
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including ...
Item does not contain fulltextThe primary objective of this 2-part phase 1/2 study was to determine ...
textabstractThe primary objective of this 2-part phase 1/2 study was to determine the maximum-tolera...
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MT...
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MT...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this...
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this...
BACKGROUND: In this phase 2 study, the authors evaluated the efficacy, safety, and tolerability of...
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in...
AbstractAlisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor....
We investigated the effects of targeting the mitotic regulators aurora kinase A and B in pediatric a...
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, a...
antileukemic activity in cell lines and primary cultures of acute myeloid leukemi
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including ...
Item does not contain fulltextThe primary objective of this 2-part phase 1/2 study was to determine ...
textabstractThe primary objective of this 2-part phase 1/2 study was to determine the maximum-tolera...
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MT...
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MT...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this...
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this...
BACKGROUND: In this phase 2 study, the authors evaluated the efficacy, safety, and tolerability of...
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in...
AbstractAlisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor....
We investigated the effects of targeting the mitotic regulators aurora kinase A and B in pediatric a...
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, a...
antileukemic activity in cell lines and primary cultures of acute myeloid leukemi
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including ...